Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 3, 2006, Pages 1012-1018

  Choo, Edna F ^a   Kurnik, Daniel ^a   Muszkat, Mordechai ^a   Ohkubo, Tadashi ^a   Shay, Sheila D ^a   Higginbotham, James N ^a   Glaeser, Hartmut ^a   Kim, Richard B ^a   Wood, Alastair J J ^a   Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LOPERAMIDE; RHODAMINE 123; TARIQUIDAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG UPTAKE; IN VIVO STUDY; ISOTOPE LABELING; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; T LYMPHOCYTE; TESTIS;

ACRIDINES; ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; DOSE-RESPONSE RELATIONSHIP, DRUG; LOPERAMIDE; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; P-GLYCOPROTEIN; PAIN; QUINOLINES; T-LYMPHOCYTES; TESTIS; TETRAHYDROISOQUINOLINES; TISSUE DISTRIBUTION;

EID: 33646790191     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.099648     Document Type: Article

References (39)

1. 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 9:650-656.
2. Allen JD and Schinkel AH (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/A BcG2). Mol Cancer Ther 1:427-434.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
4. Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
5. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
6. Dagenais C, Graff CL, and Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
7. Demeule M, Jodoin J, Gingras D, and Béliveau R (2000) P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 466:219-224.
8. Didier AD and Loor F (1995) Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer 63:263-267.
9. Fra AM, Williamson E, Simons K, and Parton RG (1994) Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae. J Biol Chem 269:30745-30748.
10. Gayet L, Dayan G, Barakat S, Labialle S, Michaud M, Cogne S, Mazane A, Coleman A, Rigal D, and Baggetto LG (2005) Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry 44:4499-4509.
11. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, and van Tellingen O (2004a) The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 53:173-178.
12. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, and van Tellingen O (2003) Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9:2849-2855.
13. Kemper EM, Verheij M, Boogerd W, Beijnen JH, and van Tellingen O (2004b) Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 40:1269-1274.
14. Kim KA, Chung J, Jung DH, and Park JY (2004) Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 60:575-581.
15. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
16. Leonard GD, Polgar O, and Bates SE (2002) ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3:1652-1659.
17. Letrent SP, Pollack GM, Brouwer KR, and Brouwer KLR (1998) Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res (NY) 15:599-605.
18. Letrent SP, Pollack GM, Brouwer KR, and Brouwer KLR (1999) Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27:827-834.
19. Lin JH and Yamazaki M (2003) Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417-454.
20. Litman T, Skovgaard T, and Stein WD (2003) Pumping of drugs by P-glycoprotein: a two-step process? J Pharmacol Exp Ther 307:846-853.
21. Mackerer CR, Clay GA, and Dajani EZ (1976) Loperamide binding to opiate receptor sites of brain and myenteric plexus. J Pharmacol Exp Ther 199:131-140.
22. Mahar Doan KM, Humphreys J, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
23. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, and Callaghan R (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403-411.
24. Martin C, Berridge G, Higgins CF, Prakash M, Charlton P, and Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol: 58:624-632.
25. Marzolini C, Tirona R, and Kim RB (2004) Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5:273-282.
26. Mayer U, Wagenaar E, Dorobet B, Beijnen JH, Borst P, and Schinkel AH (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC 833. J Clin Investig 10:2430-2436.
27. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb J, Templeton D, and Charlton P (2001) In vivo and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749-758.
28. + cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93:306-314.
29. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
30. Schinkel AH, Wagenaar E, Mol CAAM, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
31. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Investig 96:1698-1705.
32. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PI, Okamoto T, and Lisanti MP (1999) Caveolins, liquid-ordered domains and signal transduction. Mol Cell Biol 19:7289-7304.
33. Song S, Suzuki H, Kawai R, and Sugiyama Y (1999) Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27:689-694.
34. Stahl KD, van Bever W, Janssen P, and Simon EJ (1977) Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs. Eur J Pharmacol 46:199-205.
35. + lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191.
36. Thomas H and Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10:159-165.
37. Trambas C, Wang Z, Cianfriglia M, and Woods G (2001) Evidence that natural killer cells express mini P-glycoproteins but not classic 170-kDa P-glycoprotein. Br J Haematol 114:177-184.
38. Troost J, Albermann N, Emil HW, and Weiss J (2004) Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 316:705-711.
39. Xenova Ltd. (2005) Tariquidar (XR-9576): P-glycoprotein pump inhibitor, Xenova Ltd, Slough, UK.